Our study indicated that serum CRP was an independent risk factor for bone metastasis and SRE in patients with advanced RCC at cut-off value >84 U/L (p=.021), and the sensitivity and specificity was 75.9% and 85.5% respectively at ROC analysis. Here, CRP is linked to renal cell carcinoma.